Close Menu

NEW YORK – The US Food and Drug Administration expanded the approval of niraparib (GlaxoSmithKline's Zejula) as a fourth- or later-line treatment option for advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.